Molecular Imaging: Page 132

ITM, Bruce Power complete feasibility study

By AuntMinnie.com staff writers

German radiopharmaceutical group ITM Isotopen Technologien München and Canadian isotope supplier Bruce Power have completed a joint feasibility study for the irradiation of ytterbium-176 to produce lutetium-177.

October 1, 2019

Shine, Phoenix claim world record

By AuntMinnie.com staff writers

Medical isotope firm Shine Medical Technologies and nuclear technology company Phoenix are laying claim to a new world record for a nuclear fusion reaction.

October 1, 2019

CMS gets pushback on PET fee cuts

By AuntMinnie.com staff writers

Imaging organizations opposing the U.S. Centers for Medicare and Medicaid Services' (CMS) proposed payment reductions related to myocardial PET equipment and services have received support from 43 members of Congress.

October 1, 2019

Lantheus to acquire Progenics

By AuntMinnie.com staff writers

Lantheus Holdings has signed a definitive agreement to acquire oncology firm Progenics Pharmaceuticals in an all-stock transaction.

October 1, 2019

Ga-68 PSMA-11 PET interpretation criteria need work

By Wayne Forrest

Interpretation criteria for gallium-68 (Ga-68) prostate-specific membrane antigen-11 (PSMA-11) PET with CT or MRI for prostate cancer can bolster interreader agreement, but some performance issues remain, according to a study published online September 27 in the Journal of Nuclear Medicine.

October 1, 2019

Magnetic Insight wins NIH grant

By AuntMinnie.com staff writers

The U.S. National Institutes of Health (NIH) National Cancer Institute has awarded a new research grant to magnetic particle imaging (MPI) technology developer Magnetic Insight.

September 30, 2019

MBI useful in particular breast screening scenarios

By Kate Madden Yee

Molecular breast imaging (MBI) is outperformed by mammography in most breast cancer screening scenarios, but it still belongs in the breast cancer screening arsenal, according to a literature review published September 27 in the new journal Radiology: Imaging Cancer.

September 30, 2019

PET/CT beats SPECT for neuroendocrine tumors

By Wayne Forrest

PET/CT performed better than planar scintigraphy or SPECT for determining which patients with neuroendocrine tumors are most likely to benefit from peptide receptor radionuclide therapy, in a study published in the September issue of the Journal of Nuclear Medicine.

September 26, 2019

FDA approves BWXT's radiopharmaceutical

By AuntMinnie.com staff writers

U.S. government nuclear components supplier BWX Technologies (BWXT) has received approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for a generic version of indium-111 (In-111) oxyquinoline solution.

September 25, 2019

USP delays revised radiopharmaceutical standards

By AuntMinnie.com staff writers

The U.S. Pharmacopeial Convention (USP) has postponed until December 1 implementation of several revisions related to the compounding, preparation, and packaging of radiopharmaceuticals.

September 25, 2019

Rethinking Ga-68 PSMA-11 PET/CT for bone metastases

By Wayne Forrest

Researchers from the University of California, Los Angeles say it is time to reconsider guidelines in favor of broader use of gallium-68 (Ga-68) prostate-specific membrane antigen-11 (PSMA-11) PET/CT to detect bone metastases in prostate cancer patients, based on findings in their study published September 20 in the Journal of Nuclear Medicine.

September 25, 2019

GE, partners to develop PET tracers

By AuntMinnie.com staff writers

GE Healthcare is teaming up with three companies and one U.S. academic institution to develop a portfolio of PET tracers designed to better predict and monitor patient response to immunotherapies.

September 24, 2019

Previous Page

Page 132 of 614

Next Page